Preliminary studies have indicated that Bextra (valdecoxib), an arthritis drug manufactured by Pfizer, Inc., could potentially be one of the leading causes of Stevens Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme (EM) due to drug allergy reactions. These studies also indicate that Bextra, like Vioxx (another COX-2 inhibitor that was recently pulled from the shelves by its manufacturer, Merck & Co. Inc.), may be linked with greatly increased risks of cardiovascular (CV) events such as heart attacks and strokes.